[ad_1]
The information was released late on Tuesday by the health information website Stat News and later confirmed by the pharmaceutical company itself, in a statement sent to the American television channel CNN.
“As part of the ongoing global randomized controlled trials of the Oxford coronavirus vaccine, our standard review process has resulted in a pause in vaccination to allow for review of safety data,” the company said in a statement.
AstraZeneca stressed that this is “a routine action, which should occur whenever there is a potentially unexplained illness in one of the trials, while it is being investigated”, in order to ensure that “the integrity of the trials” is maintained.
“In large-scale trials, diseases happen by chance, but they need to be independently reviewed so they can be carefully controlled. We are working to speed up the review of a single event to minimize any potential impact on the testing program. We are committed to the safety of our participants and to the highest standards of conduct in our tests, ”the statement concluded.
Thus, studies on the final stage of the vaccine are suspended while the company investigates whether a report of a patient with a serious side effect is related to the product in development.
A spokesperson for AstraZeneca confirmed that the vaccination pause covers testing in the United States of America (USA) and other countries.
